TY - JOUR
T1 - Experience with rufinamide in a pediatric population
T2 - A single center's experience
AU - Vendrame, Martina
AU - Loddenkemper, Tobias
AU - Gooty, Vasu D.
AU - Takeoka, Masanori
AU - Rotenberg, Alexander
AU - Bergin, Ann M.
AU - Eksioglu, Yaman Z.
AU - Poduri, Annapurna
AU - Duffy, Frank H.
AU - Libenson, Mark
AU - Bourgeois, Blaise F.
AU - Kothare, Sanjeev V.
N1 - Funding Information:
This study was funded in part by an Investigator Initiated Grant from Eisai Pharma, Inc ., to S.V.K. and T.L. for analyzng the data.
PY - 2010/9
Y1 - 2010/9
N2 - Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and dosing schedules. It appeared efficacious in diverse epilepsy syndromes, with the highest responder rate in focal cryptogenic epilepsies (81.1% of patients with >50% response rate), and in diverse seizure types, with the highest responder rate in tonic/atonic and partial seizures (48.6% and 46.7% of patients with >50% response rate, respectively). Rufinamide was well tolerated: only 13% of patients developed side effects necessitating drug withdrawal. These findings suggest that rufinamide may possess good efficacy and tolerability, and that its efficacy may extend to epilepsy syndromes beyond Lennox-Gastaut, including both partial and generalized epilepsy syndromes.
AB - Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and dosing schedules. It appeared efficacious in diverse epilepsy syndromes, with the highest responder rate in focal cryptogenic epilepsies (81.1% of patients with >50% response rate), and in diverse seizure types, with the highest responder rate in tonic/atonic and partial seizures (48.6% and 46.7% of patients with >50% response rate, respectively). Rufinamide was well tolerated: only 13% of patients developed side effects necessitating drug withdrawal. These findings suggest that rufinamide may possess good efficacy and tolerability, and that its efficacy may extend to epilepsy syndromes beyond Lennox-Gastaut, including both partial and generalized epilepsy syndromes.
UR - http://www.scopus.com/inward/record.url?scp=77955534377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955534377&partnerID=8YFLogxK
U2 - 10.1016/j.pediatrneurol.2010.04.003
DO - 10.1016/j.pediatrneurol.2010.04.003
M3 - Article
C2 - 20691934
AN - SCOPUS:77955534377
SN - 0887-8994
VL - 43
SP - 155
EP - 158
JO - Pediatric Neurology
JF - Pediatric Neurology
IS - 3
ER -